试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
编号:NCT02002598登记状态:提前终止企业 / 申办者:Suzanne Lentzsch, MD
药物 / 成分:Bendamustine、Carfilzomib、Dexamethasone
登记的停止原因(原文):Slow accrual and loss of funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.
编号:NCT02681523登记状态:提前终止企业 / 申办者:Imperial College London
药物 / 成分:Eribulin
登记的停止原因(原文):Slow patient recruitment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Once Versus Twice Daily Iron Supplementation in Pregnant Women
编号:NCT02839096登记状态:提前终止企业 / 申办者:University of Missouri-Columbia
药物 / 成分:Placebo、Ferrous Sulfate
登记的停止原因(原文):Lack of funds, PI left University
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients
编号:NCT02991768登记状态:提前终止企业 / 申办者:University of Kansas Medical Center
药物 / 成分:Entocort、Placebos
登记的停止原因(原文):Enrollment not continued
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Efficacy of Intermittent Tiotropium in Early Childhood Wheezing
编号:NCT03199976登记状态:提前终止企业 / 申办者:Helsinki University Central Hospital
药物 / 成分:Tiotropium Bromide、Fluticasone Propionate、Salbutamol
登记的停止原因(原文):Subjects in the Salbutamol group discontinued the intervention more often due to troublesome respiratory symptoms
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
BR55 in Characterization of Ovarian Lesions
编号:NCT03493464登记状态:提前终止企业 / 申办者:Bracco Diagnostics, Inc
药物 / 成分:BR55
登记的停止原因(原文):Sponsor decision; expiration of available study agent due to long recruitment timeline.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy
编号:NCT03532542登记状态:提前终止企业 / 申办者:Sarepta Therapeutics, Inc.
药物 / 成分:Casimersen、Golodirsen
登记的停止原因(原文):The trial was stopped to reduce the clinical trial burden on participants while ensuring continued treatment via a post-trial access program with commercially available casimersen and golodirsen. Study was not terminated due to safety concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors
编号:NCT03604783登记状态:提前终止企业 / 申办者:Sumitomo Pharma America, Inc.
药物 / 成分:TP-1287
登记的停止原因(原文):Sponsor's decision to terminate further development of the program.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)
编号:NCT03675126登记状态:提前终止企业 / 申办者:Sarepta Therapeutics, Inc.
药物 / 成分:SRP-5051
登记的停止原因(原文):The sponsor has decided to integrate 5051-102 into 5051-201. Participants from 5051-102 will be eligible to enroll in 5051-201 Part B.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-09-19
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
编号:NCT03691376登记状态:提前终止企业 / 申办者:Roswell Park Cancer Institute
药物 / 成分:Aldesleukin、Autologous NY-ESO-1-specific CD8-positive T Lymphocytes、Cellular Therapy、Melphalan
登记的停止原因(原文):Lack of funding
查看官方原始记录 ↗